United Healthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2147-7
Program Prior Authorization/Medical Necessity
Medication Movantik® (naloxegol)*
P&T Approval Date 7/2018, 7/2019, 8/2020, 6/2021, 6/2022, 6/2023, 6/2024
Effective Date 9/1/2024
1. Background:
Movantik (naloxegol)* and Symproic® (naldemedine) are opioid antagonists indicated for the
treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain
including patients with chronic pain related to prior cancer or its treatment who do not require
frequent (e.g., weekly) opioid dosage escalation. Amitiza®* (lubiprostone) is indicated for the
treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in
adults and for the treatment opioid-induced constipation (OIC) in adult patients with chronic,
non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who
do not require frequent (e.g., weekly) opioid dosage escalation.
This prior authorization program is intended to encourage the use of lower cost alternatives. This
program requires a member lower cost alternatives before providing coverage for Movantik.
2. Coverage Criteriaa:
A. Initial Authorization
1. Movantik* will be approved based on BOTH of the following:
a. ONE of the following:
(1) Diagnosis of opioid-induced constipation with chronic, non-cancer pain
-OR-
(2) Diagnosis of opioid-induced constipation in patients with chronic pain related to
prior cancer diagnosis or cancer treatment who do not require frequent (e.g.,
weekly) opioid dosage escalation
-AND-
b. History of failure, contraindication or intolerance to BOTH of the following
(document date tried):
(1) lubiprostone (generic Amitiza)
-AND-
(2) Symproic
Authorization will be issued for 12 months
© 2024 UnitedHealthcare Services Inc.
1
B. Reauthorization
1. Movantik* will be approved based on the following criterion:
a. Documentation of positive clinical response to Movantik* therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Brand only Amitiza and Movantik are typically excluded from coverage
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• Notification/Prior Authorization may be in place.
4. References:
1. Amitiza [package insert]. Lexington, MA: Takeda pharmaceuticals America, Inc; November
2020.
2. Movantik [package insert]. Chicago, IL: Valinor Pharma, LLC; March 2023.
3. Symproic [package insert]. Raleigh, NC: BioDelivery Sciences International; July 2021.
Program Prior Authorization/Medical Necessity – Movantik
Change Control
Date Change
7/2018 New program.
7/2019 Annual review. No changes.
8/2020 Annual review. Updated initial authorization and references.
6/2021 Annual review. Updated references.
6/2022 Annual review. Updated references.
6/2023 Annual review. Updated references. Removed OTC step and added
step through generic Amitiza.
6/2024 Annual review. Updated background section. Added document date
tried. Referenced brand Amitiza exclusion. Updated references.
© 2024 UnitedHealthcare Services Inc.
2